A Santistue Roman*, M Bello Crespo, I Segui Gregori, M Montero Hernandez, S Gea Navarrete, E Soler Company. Hospital Pharmacist, Hospital Arnau De Villanova, Valencia, Spain

10.1136/ejhpharm-2020-eahpconf.368

Background and importance Despite the clinical benefits of therapy with control point inhibitors in several malignancies, this inhibition is closely linked to a series of immune related adverse events (irAEs). The early detection and management of these is of vital importance.

Aim and objectives To identify and describe irAEs with programmed cell death protein 1 (PD-1) inhibitors and programmed death ligand 1 (PD-L1) inhibitors in clinical practice.

Material and methods A retrospective, descriptive, observational study was conducted in a 400 bed hospital in patients treated with immunotherapy (IT) from 1 January 2016 to 30 October 2018. Variables were age, gender, type of tumour, stage, IT, irAEs and grade, cycles until irAE appearance, irAE treatment and IT suspension. The electronic medical history was reviewed in OrionClinic and IT treatment in Farmis-Oncofarm. The causality of irAEs was ascertained on the basis of the European Society for Medical Oncology (ESMO) algorithms. Statistical analysis was performed with SPSS V.15.

Results A total of 127 patients were treated with an average age of 65 years (range 36–88) and 75% were women: 76% of patients had non-microcytic lung cancer, 7% head-neck, 6% bladder, 5% breast, 4% renal, 2% melanoma and colorectal cancer. In 67% of patients, stage IV tumours were found, in 27% stage III, in 4% stage II and in 2% stage I. Nivolumab was prescribed in 54% of patients, pembrolizumab in 26%, atezolizumab in 13% and durvalumab in 7%. Fifty-two irAEs were identified. The average number of cycles until irAE appearance was 3.25 (range 1–57). The main irAEs were cutaneous (37%), gastrointestinal (23%), pneumonitis (14%) and endocrinological (8%); 64% grade I, 25% grade II, 12% grade III and no grade IV. Treatment was given for 66% of irAEs: oral corticoids (52%), topical corticoids (17%), antihistamines (12%) and hormone replacement therapy (5%). IT was resumed in 83% of patients. By the end of the study period, 31% of patients remained on treatment therapy (5%). IT was resumed in 83% of patients. By the end of the study period, 31% of patients remained on treatment (5%). IT was resumed in 83% of patients. By the end of the study period, 31% of patients remained on treatment (5%).

Conclusion and relevance The most frequent irAEs in patients receiving IT were cutaneous and gastrointestinal, mostly transitory and grades I–II. They were mostly resolved with corticotherapy and antihistamines. Management of irAEs was presented on the basis of clinical experience; cooperation of patients, caregivers and healthcare professionals is required to watch over their safety to obtain the maximum efficacy with the lowest irAEs possible.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

5PSQ-052 EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE

C Varon-Galera*, P Bury-Macias, M Lamora-Garcia, M Martinez-Gallo, K Mendoza-Paredes, I Agaz-Pampolona, M Hernandez-Gonzalez, MQ Gorgas-Torner, B Montoro-Romnaro, Vall Hebron Barcelona Hospital Campus, Department of Hospital Pharmacy, Barcelona, Spain; Vall Hebron Barcelona Hospital Campus, Department of Nephrology, Barcelona, Spain; Vall Hebron Barcelona Hospital Campus, Department of Immunology, Barcelona, Spain

10.1136/ejhpharm-2020-eahpconf.369

Background and importance Biosimilar drugs should have proven clinical efficacy comparable with the referring brand to obtain authorisation from medicine regulatory agencies. Nevertheless, the effectiveness and safety of off-label uses are not always proved.

Aim and objectives The endpoint of this study was to evaluate the early effectiveness and safety of biosimilar rituximab compared with the referring brand for an off-label use: glomerular inflammatory renal disease.

Material and methods This was an observational retrospective study in patients with glomerular inflammatory disease treated with rituximab (1 g single dose or 1 g two doses). Patients receiving rituximab for the first time between March 2018 and March 2019 were included. Information on patient demographics, underlying disease and associated treatment was collected from the patient medical records. Laboratory data including creatinine, proteinuria, leucocyte and lymphocyte count were collected before (0–60 previous days) and after (0–60 days after) administration of rituximab.

Results Six patients (mean age 59 years (26–74); 50% women) with baseline 6.52±2.00×10 9/L leucocyte count, 2.28±1.10×10 9/L lymphocyte count, 1.63±1.04 mg/dL creatinine and 6.84±3.36 g/24 hours proteinuria were treated with biosimilar rituximab. Thirteen patients (mean age 58 years (25–81); 30% women) with baseline 9.80±4.62×10 9/L leucocyte count, 1.92±1.13×10 9/L lymphocyte count, 1.61±0.85 mg/dL creatinine and 5.81±4.55 g/24 hours proteinuria were treated with the referring brand. Treatment with rituximab administration, these values were 6.13±1.94×10 9/L leucocyte count, 1.30±0.59×10 9/L lymphocyte count, 1.16±1.19 mg/dL creatinine, 3.29±0.58 g/24 hours and proteinuria for the biosimilar group, and 8.77±3.78×10 9/L leucocyte count, 1.67±1.13×10 9/L lymphocyte count, 1.56±1.19 mg/dL creatinine and 3.36±2.20 g/24 hours proteinuria for the brand group. After rituximab administration, these values were 6.13±1.94×10 9/L leucocyte count, 1.30±0.59×10 9/L lymphocyte count, 1.16±1.19 mg/dL creatinine and 3.29±0.58 g/24 hours proteinuria for the biosimilar group, and 8.77±3.78×10 9/L leucocyte count, 1.67±1.13×10 9/L lymphocyte count, 1.56±1.19 mg/dL creatinine and 3.36±2.20 g/24 hours proteinuria for the brand group. After rituximab administration, these values were 6.13±1.94×10 9/L leucocyte count, 1.30±0.59×10 9/L lymphocyte count, 1.16±1.19 mg/dL creatinine and 3.29±0.58 g/24 hours proteinuria for the biosimilar group, and 8.77±3.78×10 9/L leucocyte count, 1.67±1.13×10 9/L lymphocyte count, 1.56±1.19 mg/dL creatinine and 3.36±2.20 g/24 hours proteinuria for the brand group.